ADSTILADRIN Is an Intravesical Instillation Given Once Every 3 Months

ADSTILADRIN offers seamless integration into your urology practice, reducing the treatment burden

Yellow checkmark icon

Familiar intravesical instillation

Yellow checkmark icon

Quarterly dosing:
once every 3 months

Yellow checkmark icon

in your urology office

Yellow checkmark icon

No required reconstitution or dilution

No Bacillus Calmette-Guérin (BCG) coadministration
is required with ADSTILADRIN

  • The recommended dose of ADSTILADRIN (nadofaragene firadenovec-vncg) is 75 mL at a concentration of 3 x 1011 viral particles/mL
  • Premedication with an anticholinergic is recommended before each instillation of ADSTILADRIN


Neal Shore, MD, FACS, a clinician from the ADSTILADRIN clinical trials, shares important information about implementing ADSTILADRIN in your office.

ADSTILADRIN Instructions for Use Downloadable Guide

Related resource Download

For more on dosing as well as administration details, please download the Instructions for Use and see full Prescribing Information

Sign Up to Receive Information and Updates on ADSTILADRIN (nadofaragene firadenovec-vncg)

Form Toggle

Your Information

Your Mailing Address

*Required field.

Reference: ADSTILADRIN. Package insert. Ferring Pharmaceuticals, Inc; 2023.

Important Safety Information


ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.


CONTRAINDICATIONS: ADSTILADRIN is contraindicated in patients with prior hypersensitivity reactions to interferon alfa or to any component of the product.


  • Risk with delayed cystectomy: Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.
  • Risk of disseminated adenovirus infection: Persons who are immunocompromised or immunodeficient may be at risk for disseminated infection from ADSTILADRIN due to low levels of replication-competent adenovirus. Avoid ADSTILADRIN exposure to immunocompromised or immunodeficient individuals.

DOSAGE AND ADMINISTRATION: Administer ADSTILADRIN by intravesical instillation only. ADSTILADRIN is not for intravenous use, topical use, or oral administration.

USE IN SPECIFIC POPULATIONS: Advise females of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 3 months after the last dose.

ADVERSE REACTIONS: The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination urgency), creatinine increased, hematuria (blood in urine), phosphate decreased, chills, pyrexia (fever), and dysuria (painful urination).

You are encouraged to report negative side effects of prescription drugs to FDA. Visit or call 1-800-332-10881-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING1-888-FERRING.

Please see full Prescribing Information for ADSTILADRIN.

Close popup

Are you a US healthcare professional?

Latest Updates


Effective April 1, 2024, ADSTILADRIN has established an average sales price (ASP) in accordance with the guidelines set forth by the Centers for Medicare & Medicaid Services Part B. This determination is a significant milestone for Ferring Uro-Oncology and represents our commitment to providing transparency and value to our customers.

To get ongoing updates about ADSTILADRIN, please sign up here.